← Back to front page
United States · Platforms & data · Yahoo Finance

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

Published by Yahoo Finance · United States 8 h ago
Oculis Holding AG
Oculis Holding AG · Yahoo Finance

Detailed summary

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading.…

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic neuritis

Oculis will host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and the ongoing PIONEER program in optic neuropathies

ZUG, Switzerland, November 16, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address critical unmet medical needs in neuro-ophthalmology, neurology, and ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Privosegtor for the treatment of acute multiple sclerosis (MS) relapses.

The FDA clearance follows pre-IND feedback from the FDA Division of Neurology-2, which confirmed that Oculis can cross-reference data from the open Privosegtor ophthalmology-related IND. The FDA further supported the proposed clinical development strategy, which would include patients with Multiple Sclerosis (MS) who experience Optic Neuritis (ON) as well as other types of relapses, such as ambulatory relapses, and a primary endpoint as early as three months, using the same 3mg/kg daily dose for five days as in PIONEER-1.

Optic neuritis is frequently observed both as the initial clinical presentation of MS and during acute relapses, serving as a pathophysiological model of acute demyelination that is potentially generalizable to other acute MS relapses. In the completed Phase 2 ACUITY study, which evaluated a broad population of patients with ON, including those with and without MS, Privosegtor demonstrated a promising neuroprotective effect.

Building on these positive findings, expanding into acute MS relapses is a natural evolution for the Privosegtor program.

Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading